HBM Holdings expands collaboration with Umoja Biopharma for CAR-T cell products

HBM Holdings Limited announced that its wholly-owned subsidiary, Nona Biosciences (Suzhou) Co., Ltd., has signed an evaluation and license agreement with Umoja Biopharma, Inc. This agreement aims to develop *in vivo* CAR-T cell products by combining Nona Biosciences' HCAb Harbour Mice® and NonaCarFx™ platforms with Umoja Biopharma's VivoVect™ platform. This collaboration builds upon a strategic partnership initiated in September 2024.

Under the terms, Nona Biosciences is eligible for an upfront payment, potential option exercise fees, and milestone payments related to the discovery and development of specific programs. Umoja Biopharma will be responsible for all subsequent product development and commercialization efforts.

Umoja Biopharma is a clinical-stage biotechnology company focused on developing *in vivo* cell therapies to enhance CAR-T treatment in oncology and autoimmunity using its VivoVect™ *in vivo* gene delivery technology. The company's Louisville, Colorado facility supports its lentiviral vector development and manufacturing.